吖啶片获批在即｜金马药业集团携手北京大兴区共谋发展新篇

Core Viewpoint - The strategic partnership between Daxing District and Jinma Pharmaceutical Group aims to enhance innovation and development in the pharmaceutical industry, particularly focusing on the approval and commercialization of the new drug, Amber Tetrahydroaminoacridine Tablets [1][3]. Group 1: Strategic Collaboration - Daxing District leaders met with Jinma Pharmaceutical Group to discuss the establishment of a headquarters and innovation center, new drug production, and commercialization efforts [3][9]. - The collaboration is expected to empower the capital's pharmaceutical and health industry, aligning with the district's goal of becoming a hub for life sciences [3][5]. Group 2: Regional Advantages - Daxing District is positioned as a core hub within the capital metropolitan area, benefiting from unique policy advantages due to its location in the airport economic zone, free trade zone, and comprehensive bonded zone [5][7]. - The district aims to develop three trillion-level industrial clusters, with a focus on life and health as a core engine for growth [5][7]. Group 3: Pharmaceutical Development - The "China Pharmaceutical Valley" is highlighted as the largest national-level biopharmaceutical park, featuring numerous high-tech enterprises and a complete service system from research to production [7][9]. - Jinma Pharmaceutical's focus on innovative drugs in the neurological field aligns with the district's strategic direction and development requirements [9][11]. Group 4: Future Plans - Jinma Pharmaceutical plans to establish a high-standard production and commercialization base for Amber Tetrahydroaminoacridine Tablets, leveraging the park's top-tier resources [14][15]. - The company aims to accelerate the development of innovative drugs for moderate to severe indications and acute ischemic stroke, utilizing the resources of six national clinical research centers [15][16]. Group 5: Commitment to Innovation - The partnership is seen as a commitment to building a future of pharmaceutical innovation, with both parties expressing strong confidence in the collaboration's potential [17][21]. - Jinma Pharmaceutical's strategic vision includes establishing a headquarters and innovation center in Beijing, aiming for a comprehensive transition to an innovative pharmaceutical company within 3-5 years [13][19].